Stock AnalizUltragenyx Pharmaceutical Inc. RARE
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Ultragenyx Pharmaceutical Inc. (RARE) is a healthcare company listed in the US with a market value of about $1.6B. In the twelve months to September 30, 2026 it had revenue of $730M and net income of -$524M, a net margin of -71.8%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 20% a year, a 5-year average ROIC of -122%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $730M | $673M | $560M | $434M | $363M | $351M | $271M | $104M | $51M | $3M | $133000 |
| Net income | -$524M | -$575M | -$569M | -$607M | -$707M | -$454M | -$187M | -$403M | -$198M | -$302M | -$246M |
| Free cash flow | -$442M | -$472M | -$421M | -$519M | -$497M | -$412M | -$176M | -$370M | -$295M | -$257M | -$171M |
| EPS (diluted) | $-5.18 | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | $-7.12 | $-3.97 | $-7.12 | $-6.21 |
| Net margin | -71.8% | -85.4% | -101.6% | -139.9% | -194.7% | -129.2% | -68.8% | -388.3% | -383.8% | -11567.3% | -184900.0% |
| ROIC | — | — | -143.4% | -178.2% | -133.7% | -31.3% | -21.7% | -48.5% | -48.2% | -81.4% | -41.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 20 analysts is $25.35, 58% above the current price; targets range from $16.00 to $39.00; the consensus rating is “Buy”; expected EPS is $-3.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Ultragenyx Pharmaceutical stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Ultragenyx Pharmaceutical pay a dividend?
Not currently.
Is Ultragenyx Pharmaceutical a good stock to buy?
We do not give buy or sell advice. Ultragenyx Pharmaceutical scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.